Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes

Acute myeloid leukemia (AML) is a heterogeneous disease with variable responses to therapy. Cytogenetic and genomic features are used to classify AML patients into prognostic and treatment groups. However, these molecular characteristics harbor significant patient-to-patient variability and do not fully account for AML heterogeneity. RNA-based classifications have also been applied in AML as an alternative approach, but transcriptomic grouping is strongly associated with AML morphologic lineages. We used a training cohort of newly diagnosed AML patients and conducted unsupervised RNA-based classification after excluding lineage-associated genes. We identified three AML patient groups that have distinct biological pathways associated with outcomes. Enrichment of inflammatory pathways and downregulation of HOX pathways were associated with improved outcomes, and this was validated in 2 independent cohorts. We also identified a group of AML patients who harbored high metabolic and mTOR pathway activity, and this was associated with worse clinical outcomes. Using a comprehensive reverse phase protein array, we identified higher mTOR protein expression in the highly metabolic group. We also identified a positive correlation between degree of resistance to venetoclax and mTOR activation in myeloid and lymphoid cell lines. Our approach of integrating RNA, protein, and genomic data uncovered lineage-independent AML patient groups that share biologic mechanisms and can inform outcomes independent of commonly used clinical and demographic variables; these groups could be used to guide therapeutic strategies.

[1]  M. Minden,et al.  Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia , 2019, Science Translational Medicine.

[2]  J. Budczies,et al.  Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival , 2019, Journal of advanced research.

[3]  C. Simillion,et al.  CD8+ T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia , 2019, Leukemia.

[4]  Chenyue W. Hu,et al.  A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia , 2019, Nature Biomedical Engineering.

[5]  J. Orange,et al.  Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotype , 2019, Leukemia & lymphoma.

[6]  Dirk Mossmann,et al.  mTOR signalling and cellular metabolism are mutual determinants in cancer , 2018, Nature Reviews Cancer.

[7]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[8]  E. Olejniczak,et al.  A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. , 2018, Cancer discovery.

[9]  Haocai Chang,et al.  Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer , 2018, Cell Death & Disease.

[10]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[11]  Inigo Martincorena,et al.  Precision oncology for acute myeloid leukemia using a knowledge bank approach , 2017, Nature Genetics.

[12]  K. Coombes,et al.  MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells , 2016, Oncotarget.

[13]  Alex M. Fichtenholtz,et al.  Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. , 2016, Blood.

[14]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[15]  Joshua A. Bittker,et al.  Correlating chemical sensitivity and basal gene expression reveals mechanism of action , 2015, Nature chemical biology.

[16]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[17]  E. Eklund,et al.  HoxA10 Terminates Emergency Granulopoiesis by Increasing Expression of Triad1 , 2015, The Journal of Immunology.

[18]  Peng Qiu,et al.  Single‐cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3‐ITD‐mutated AML stem/progenitor cells , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[19]  Daniel J Weisdorf,et al.  Acute Myeloid Leukemia. , 2015, The New England journal of medicine.

[20]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[21]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[22]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[23]  E. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[24]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[25]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[26]  J. Tamburini,et al.  The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia , 2012, Leukemia.

[27]  Chris Williams,et al.  RNA-SeQC: RNA-seq metrics for quality control and process optimization , 2012, Bioinform..

[28]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[29]  K. Baggerly,et al.  Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. , 2010, Blood.

[30]  K. Baggerly,et al.  Targeting of mTORC 1 / 2 by the mTOR kinase inhibitor PP 242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment , 2012 .

[31]  B. Viollet,et al.  AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 , 2011, Nature Cell Biology.

[32]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[33]  Jiang Li,et al.  mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells , 2010, Molecular Cancer.

[34]  Chang Hwa Jung,et al.  mTOR regulation of autophagy , 2010, FEBS letters.

[35]  G. Pejler,et al.  Canine Uterine Bacterial Infection Induces Upregulation of Proteolysis-Related Genes and Downregulation of Homeobox and Zinc Finger Factors , 2009, PloS one.

[36]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[37]  H. Taylor,et al.  Thrombin and interleukin-1beta decrease HOX gene expression in human first trimester decidual cells: implications for pregnancy loss. , 2009, Molecular human reproduction.

[38]  Peter J. Woolf,et al.  GAGE: generally applicable gene set enrichment for pathway analysis , 2009, BMC Bioinformatics.

[39]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[40]  K. Coombes,et al.  HOX expression patterns identify a common signature for favorable AML , 2008, Leukemia.

[41]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[42]  T. Golub,et al.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.

[43]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.

[45]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[46]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[47]  J. Downing,et al.  Acute myeloid leukemia. , 1999, The New England journal of medicine.

[48]  Z. Estrov,et al.  Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. , 1996, Blood.